Several potential approaches have been tested in preclinical settings, including the inhibition of pathogenic CD4 T cell recruitment using a neutralizing monoclonal antibody against α4β7 that was successful at preventing binding of α4β7-bearing CD4 T cells to MAdCAM-1 in the liver and intestine and resulted in attenuated liver inflammation and fibrosis (67). The gene discussed is CD4; the disease is inflammatory response.